

BÖLÜM 15

STEROİD BAĞIMLILIĞI GELİŞEN SUBAKUT TİROİDİT OLGUSUNDA KOLŞİSİN KULLANIMI

Kadircan KARATOPRAK ¹

GİRİŞ

Tiroidit, tiroid bezinin iltihabi hastalıklarını tanımlayan genel bir terim olup, farklı klinik görünüm ve etiyolojik faktörler ile karakterize heterojen bir bozukluk grubunu kapsar. Tiroiditler, etyolojilerine, klinik seyirlerine ve fonksiyonel sonuçlarına göre sınıflandırılabilir. Klinik pratikte en sık kullanılan yaklaşım, hastalığın ağrı ile seyredip seyretmediğine göre yapılan sınıflamadır. Bu ayrım, tanısal süreçte yol gösterici olup tedavi stratejilerinin belirlenmesinde de önem taşır (1).

Tablo 15.1 Tiroiditlerin ağrı ve hassasiyet varlığına göre sınıflandırılması

Hastalık	Eş anlamlıları / nedenleri
Tiroid ağrısı ve hassasiyeti olanlar	
Subakut tiroidit	Subakut granümatöz tiroidit, Subakut nonsüpuratif tiroidit, de Quervain tiroiditi Dev hücreli tiroidit
Enfeksiyöz tiroidit	Akut veya kronik tiroidit
Radyasyon ilişkili tiroidit	
Travma veya palpasyon ilişkili tiroidit	

¹ Uzm. Dr., Uludağ Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Hastalıkları AD., karatoprak.kadircan@gmail.com, ORCID iD: 0000-0001-5205-9539

KAYNAKLAR

1. Bindra A, Braunstein GD. Thyroiditis. *American Family Physician*. 2006;73(10): 1769–1776.
2. Subacute thyroiditis – UpToDate. (Online) https://www.uptodate.com/contents/subacute-thyroiditis?search=subakut%20tiroidit&source=search_result&selectedTitle=1~30&usage_type=default&display_rank=1
3. Tabassom A, Chippa V, Edens MA. De Quervain Thyroiditis. *StatPearls (Internet)*. StatPearls Publishing; 2023. <https://www.ncbi.nlm.nih.gov/books/NBK526066/>
4. Lazarus JH. Silent thyroiditis and subacute thyroiditis. In: The Thyroid: A Fundamental and Clinical Text, 7th Ed, Braverman LE, Utiger RD (Eds), Lippincott Williams & Wilkins, Philadelphia 1996. p.577.
5. Martino E, Buratti L, Bartalena L, et al. High prevalence of subacute thyroiditis during summer season in Italy. *Journal of Endocrinological Investigation*. 1987;10(3): 321–323. doi:10.1007/BF03348138
6. Desailoud R, Hober D. Viruses and thyroiditis: an update. *Virology Journal*. 2009;6: 5. doi:10.1186/1743-422X-6-5
7. Christensen J, O'Callaghan K, Sinclair H, et al. Risk factors, treatment and outcomes of subacute thyroiditis secondary to COVID-19: a systematic review. *Internal Medicine Journal*. 2022;52(4): 522–529. doi:10.1111/imj.15432
8. Fatourehchi V, Aniszewski JP, Fatourehchi GZE, et al. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. *The Journal of Clinical Endocrinology and Metabolism*. 2003;88(5): 2100–2105. doi:10.1210/jc.2002-021799
9. Benbassat CA, Olchovsky D, Tsvetov G, et al. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. *Journal of Endocrinological Investigation*. 2007;30(8): 631–635. doi:10.1007/BF03347442
10. Volpé R, Row VV, Ezrin C. Circulating viral and thyroid antibodies in subacute thyroiditis. *The Journal of Clinical Endocrinology and Metabolism*. 1967;27(9): 1275–1284. doi:10.1210/jcem-27-9-1275
11. Ohsako N, Tamai H, Sudo T, et al. Clinical characteristics of subacute thyroiditis classified according to human leukocyte antigen typing. *The Journal of Clinical Endocrinology and Metabolism*. 1995;80(12): 3653–3656. doi:10.1210/jcem.80.12.8530615
12. Alper AT, Hasdemir H, Akyol A, et al. Incessant ventricular tachycardia due to subacute thyroiditis. *International Journal of Cardiology*. 2007;116(1): e22–24. doi:10.1016/j.ijcard.2006.08.068
13. Sherman SI, Ladenson PW. Subacute thyroiditis causing thyroid storm. *Thyroid: Official Journal of the American Thyroid Association*. 2007;17(3): 283. doi:10.1089/thy.2007.0070
14. Nishihara E, Ohye H, Amino N, et al. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. *Internal Medicine (Tokyo, Japan)*. 2008;47(8): 725–729. doi:10.2169/internalmedicine.47.0740
15. Slatosky J, Shipton B, Wahba H. Thyroiditis: differential diagnosis and management. *American Family Physician*. 2000;61(4): 1047–1052, 1054.
16. Matsumoto Y, Amino N, Kubota S, et al. Serial changes in liver function tests in patients with subacute thyroiditis. *Thyroid: Official Journal of the American Thyroid Association*. 2008;18(7): 815–816. doi:10.1089/thy.2007.0374
17. Park SY, Kim E-K, Kim MJ, et al. Ultrasonographic characteristics of subacute granulomatous thyroiditis. *Korean Journal of Radiology*. 2006;7(4): 229–234. doi:10.3348/kjr.2006.7.4.229
18. Ray I, D'Souza B, Sarker P, et al. Management of Subacute Thyroiditis – A Systematic Review of Current Treatment Protocols. *International Journal of General Medicine*. 2022;15: 6425–6439. doi:10.2147/IJGM.S366784
19. Yamamoto M, Saito S, Sakurada T, et al. Effect of prednisolone and salicylate on serum thyrog-

- lobulin level in patients with subacute thyroiditis. *Clinical Endocrinology*. 1987;27(3): 339–344. doi:10.1111/j.1365-2265.1987.tb01160.x
20. Duan L, Feng X, Zhang R, et al. Short-Term Versus 6-Week Prednisone In The Treatment Of Subacute Thyroiditis: A Randomized Controlled Trial. *Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2020;26(8): 900–908. doi:10.4158/EP-2020-0096
 21. Hepsen S, Akhanli P, Sencar ME, et al. The Evaluation of Low – and High-Dose Steroid Treatments in Subacute Thyroiditis: A Retrospective Observational Study. *Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2021;27(6): 594–600. doi:10.1016/j.eprac.2020.11.009
 22. Tian Z, Su Y, Zhang M, et al. Successful Management of Recurrent Subacute Thyroiditis by Adding Colchicine to Glucocorticoid Treatment: A Case Series Study. *Hormone and Metabolic Research = Hormon – Und Stoffwechselforschung = Hormones Et Metabolisme*. 2020;52(10): 712–717. doi:10.1055/a-1148-2260
 23. Antonopoulos AS, Papanikolaou E, Vogiatzi G, et al. Anti-inflammatory agents in peripheral arterial disease. *Current Opinion in Pharmacology*. 2018;39: 1–8. doi:10.1016/j.coph.2017.11.001
 24. Drenth JPH, van der Meer JWM. The inflammasome--a linebacker of innate defense. *The New England Journal of Medicine*. 2006;355(7): 730–732. doi:10.1056/NEJMcibr063500
 25. Wang Y, Viollet B, Terkeltaub R, et al. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. *Annals of the Rheumatic Diseases*. 2016;75(1): 286–294. doi:10.1136/annrheumdis-2014-206074
 26. Roubille F, Kritikou E, Busseuil D, et al. Colchicine: an old wine in a new bottle? *Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry*. 2013;12(1): 14–23. doi:10.2174/1871523011312010004
 27. Robertson S, Martínez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. *Clinical Science (London, England: 1979)*. 2016;130(14): 1237–1246. doi:10.1042/CS20160090
 28. Bahçecioğlu AB, Erdoğan MF. Colchicine as a Steroid-Sparing Agent in Relapsing and Steroid-Dependent Subacute Thyroiditis: Preliminary Observations. *Thyroid: Official Journal of the American Thyroid Association*. 2024;34(11): 1444–1446. doi:10.1089/thy.2024.0261